Interaction of piroxicam with mitochondrial membrane and cytochrome c  by Chakraborty, Hirak et al.
1768 (2007) 1138–1146
www.elsevier.com/locate/bbamemBiochimica et Biophysica ActaInteraction of piroxicam with mitochondrial membrane and cytochrome c
Hirak Chakraborty a, Prabir K. Chakraborty b, Sanghamitra Raha b,
Parikshit C. Mandal a, Munna Sarkar a,⁎
a Chemical Sciences Division, Saha Institute of Nuclear Physics, 1/AF, Bidhannagar, Calcutta-700 064, India
b Crystallography and Molecular Biology Division, Saha Institute of Nuclear Physics, 1/AF, Bidhannagar, Calcutta-700 064, India
Received 4 September 2006; received in revised form 5 January 2007; accepted 9 January 2007
Available online 17 January 2007Abstract
Modulation of surface properties of biomembranes by any ligand leading to permeabilization, fusion, rupture, etc. is a fundamental requirement
for many biological processes. In this work, we present the interaction of piroxicam, a long acting Non-Steroidal Anti-Inflammatory Drug
(NSAID) with isolated mitochondria, membrane mimetic systems, intact cells and a mitochondrial protein cytochrome c. Dye permeabilization
study on isolated mitochondria indicates that piroxicam can permeabilize mitochondrial membrane. Direct imaging by Scanning Electron
Microscope (SEM) shows that piroxicam induces changes in mitochondrial membrane morphology leading to fusion and rupture. Transmission
Electron Microscope (TEM) imaging of piroxicam treated DMPC vesicles and mixed micelles formed from CTAB and SDS show that causing
membrane fusion is a general property of piroxicam at physiological pH. In intact cells viz., V79 Chinese Hamster lung fibroblast, piroxicam is
capable of releasing cytochrome c from mitochondria into the cytosol in a dose dependent manner along with the enhancement of downstream
proapoptotic event viz., increase in caspase-3 activity. We have also shown that piroxicam can reduce cytochrome c within a time frame relevant
to its lifetime in blood plasma. UV-visible spectroscopy has been used to study the reaction mechanism and kinetics in detail, allowing us to
propose and validate a Michaelis–Menten like reaction scheme. CD spectroscopy shows that small but significant changes occur in the structure of
cytochrome c when reduced by piroxicam.
© 2007 Elsevier B.V. All rights reserved.Keywords: NSAIDs; Mitochondria; Membrane fusion; Cytochrome c; Kinetics; Optical spectroscopy1. Introduction
Modification of the surface properties of membranes by
any ligand could lead to several phenomena like aggrega-
tion, leakage of trapped contents or permeabilization, fusion,
etc. Such modulation of surface properties is a fundamental
requirement for many biological processes [1]. Piroxicam [4-Abbreviations: NSAID, Nonsteroidal anti-inflammatory drug; SEM, Scan-
ning electron microscope; TEM, Transmission electron microscope; DMPC,
Dimyristoyl phosphatidylcoline; COX, Cyclooxygenase; MOPS, 3-Morpholi-
nopropane sulphonic acid; DMSO, Dimethyl sulfoxide; PBS, Phosphate buffer
saline; EGTA, Ethylene glycol-bis(β-aminoethyl ether)-N,N,N′,N′-tetraacetic
acid; EDTA, Ethylenediaminetetraaceticacid; PTA, Phosphotungstic acid; CD,
Circular dichroism; PMSF, Phenylmethylsulfonyl fluoride; PVDF, Polyvinyli-
dene difluoride
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doi:10.1016/j.bbamem.2007.01.004hydroxy-2-methyl-N-(pyridin-2-yl) -2H-1,2-benzothiazine-3-
carboxamide 1,1-dioxide], a drug belonging to the oxicam
group of NSAIDs, is not only a good anti-inflammatory
agent, but also show chemopreventive and chemosuppressive
effects in different cancer cell lines and animal models [2–
4]. The molecular mechanism behind its anti cancer effect is
not yet fully understood. Piroxicam strongly interacts with
membrane mimetic systems like micelles and vesicles [5–8].
Different membrane parameters viz. electrostatics and
hydrophobicity, affect the transformation or switchover
between different prototropic forms of piroxicam in such a
way so as to exert a profound effect in dictating which
structural form will predominate in solution and would be
incorporated in the membrane mimetic systems. To extend
our study to biomembranes we chose mitochondrial
membrane. Mitochondria are in general a very good phar-
macological target [9,10]. It is known that several drugs
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potential, respiration, energy coupling and can also lead to
outer membrane permeabilization [9]. Mitochondrial outer
membrane permeabilization results in release of proteins like
cytochrome c, normally found in the space between the
inner and outer mitochondrial membranes. Cytochrome c
release in the cytosol causes caspase activation that
orchestrates the downstream events associated with apopto-
sis [11,12]. Hence, affecting mitochondrial membrane by
drugs is an important strategy in chemotherapy [11].
Conventional chemotherapeutic agents result in mitochon-
drial permeabilization through an indirect way, via pro-
apoptotic second messengers, whose nature depends on the
apoptosis inducing agent. Such secondary messengers, for
example BH3-only members of the Bcl-2 protein family and
other proteins, activate the pro-apoptotic BH123 proteins,
Bax and Bak, to oligomerize and insert into the outer
mitochondrial membrane leading to mitochondrial outer
membrane permeabilization [11,12]. This initiates the
down-stream cascade of pro-apoptotic events. COX-2
inhibitors like NS-398 and celecoxib have been shown to
induce apoptosis mediated by the release of cytochrome c
from mitochondria with the consequent activation of
downstream caspases like caspase-3, caspase-8 and cas-
pase-9, etc. [13,14]. Several different reasons for the release
of cytochrome c by these COX-2 inhibitors have been pro-
posed, of which modulation of mitochondrial morphology is
a possibility.
In this study we are interested to see if piroxicam, a COX-
inhibitor, can exert its effect on mitochondrial membrane
morphology, thereby leading to the mitochondrial permeabi-
lization. To do so, we have carried out the mitochondrial
permeabilization study with cell free isolated mitochondria in
presence of piroxicam only. The modulation of mitochondrial
membrane morphology by piroxicam has also been directly
imaged by Scanning Electron Microscope. To see whether the
effect of piroxicam on mitochondrial membrane can have any
consequence on cellular processes, we have extended our
studies to intact cells. Finally, we show that piroxicam can
directly interact with the mitochondrial protein cytochrome c
in vitro, within a time frame relevant to its lifetime in blood
plasma. UV-Visible absorption and CD-spectroscopy have
been used to study the slow kinetics of interaction of
piroxicam with cytochrome c. We are aware that at the cellular
level, the effect of piroxicam can also occur via several other
parallel pathways e.g., by inducing secondary effectors
involved in the physiological control of apoptosis, etc.; but
the fusion event observed in the membrane mimetic systems
implies that there is a very strong physical interaction of
piroxicam with mitochondrial membrane. So, in this study, we
only aim to demonstrate the effect of piroxicam at four levels,
on isolated mitochondrial membrane, on membrane mimetic
systems, on cellular mitochondria and on the mitochondrial
protein cytochrome c. Identification of pathways other than
modulation of mitochondrial morphology for the release of
cytochrome c and caspase activation in intact cells is the sub-
ject of a separate study.2. Experimental procedures
2.1. Reagents
Piroxicam, DMPC and MOPS were purchased from Sigma Chemicals (US)
and were used without further purification. Stock solution of piroxicam of
concentration 3 mM was prepared in DMSO (Merck, Germany) and the exact
concentration was adjusted by corresponding buffer. Mitotracker Green FM®
was purchased from Molecular Probes, USA. Cytochrome c and Glycine were
purchased from SISCO Research Laboratory (SRL), India.
2.2. Cell culture and treatment
Chinese hamster lung fibroblast V79 cells were grown in minimal essential
medium supplemented with 10% fetal bovine serum (Sigma) and antibiotics
(penicillin and streptomycin) at 37 °C in a humidified 5% CO2 atmosphere in
plastic petridishes. Cells were grown to confluency and fresh mediumwas added
along with 20, 40 100 μM piroxicam. Equivalent amount of DMSO was added
to the control cells to compensate the DMSO present in solution when piroxicam
is diluted from stock DMSO solution.
2.3. Immunoblot analysis
After treatment with 1 μM staurosporine (Almone Laboratories, Israel),
piroxicam at concentration of 20, 40 and 100 μM respectively, cells were washed
in PBS buffer (pH 7.4) and suspended in lysis buffer (20 mM Tris, 1 mM EGTA,
1 mM EDTA, 5 mM NaF and a cocktail of protease inhibitors of 10 μM pepstatin
A, 10 μM leupeptin, and 1 mM PMSF, pH 7.5). Cells were ruptured by rapid
freeze–thaw and homogenized on ice. Lysed cells and nuclei were pelleted by
centrifugation at 1000×g for 10 min. The supernatant was centrifuged further at
15000×g for 40 min at 4 °C. The resultant supernatant was designated as the
cytosolic fraction, which was used for the detection of cytochrome c. The
supernatant was taken for SDS-polyacrylamide gel electrophoresis (SDS-PAGE).
Protein content was quantified according to Bradford [15] and then solubilized in
Laemmli sample buffer. The samples were boiled for 5 min at 100 °C and loaded
onto a 15% acrylamide gel. Electrophoresis was carried out at a constant voltage of
130 V. Cellular proteins were transferred electrophoretically to a PVDF membrane
using an Atto Electroblotter apparatus. The transfer buffer (pH 8.3) contained
96 mM glycine, 10 mM Tris, and 10% methanol. The transfer was carried out for
50 min at constant current of 160 mA. Hydrophobic or nonspecific sites were
blocked overnight at 4 °C with 5% BSA in Tris-buffered saline (50 mM Tris and
150 mM NaCl) containing 0.1% Tween 20 (TBS-T). Membranes were washed
four times for 15 min in TBS-T. The blots were probed with the primary antibody
anti-cytochrome c (Cell Signaling Technology, USA) and anti-β-actin (Sigma) in
TBS-T, 1% bovine serum albumin for 2 h at room temperature. Membranes were
washed four times for 15 min and incubated for 1 h at room temperature with
alkaline phosphatase (ALP)-conjugated secondary antibody (1:1000) in TBS-T
containing 1% BSA (pH 7.5). Secondary antibodies consisted of ALP-conjugated
anti-rabbit IgG (Oncogene Research, USA) for cytochrome c and ALP-conjugated
anti-mouse IgG for β-actin (Oncogene Research, USA). PVDF membranes were
washed four times for 15 min, and cytochrome c and β-actin were detected
colorimetrically with NBT-BCIP as substrate. Western blots were scanned by a
UMAX Astra Scanner and the bands were quantified by using Scion Image Beta
4.02 software from Scion Corporation, USA.
2.4. Isolation of mitochondria
Cells were washed in PBS and suspended in lysis buffer. Cells were ruptured
by rapid freeze–thaw and homogenized on ice. Lysed cells and nuclei were
pelleted by centrifugation at 1000×g for 10 min. The supernatant was centrifuged
further at 15,000×g for 40 min at 4 °C. Pellet of Mitochondria was collected.
2.5. Measurement of caspase-3 activity
Caspase-3 assay was done by the caspase-3 fluorescence assay kit from BD-
Pharmingen, following the protocol mentioned in the kit. Caspase-3 activity is
given in arbitrary fluorescence units.
Fig. 1. (A) Fluorescence spectra ofMitoTracker Green FM in PBS buffer (- - - - -)
and in presence of isolated mitochondria in the same buffer (——) at pH 7.4,
λexc=490 nm and (B) Plot of % relative fluorescence intensity (at 516 nm) of
Mito Tracker Green FM (20 nM) incorporated in mitochondria vs. time in control
(○) (correlation coefficient=0.98) and in presence of 20 μM piroxicam (▴)
(correlation coefficient=0.99). Plot of % relative fluorescence intensity of Mito
Tracker Green FM (20 nM) in presence of piroxicam (20 μM) but in absence of
any isolated mitochondria (□). Data are presented as the mean±S.D. for three
different experiments.
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Fluorescence measurements were performed using Hitachi spectrofluori-
meter model F 4010. All emission spectra were corrected for instrument
response at each wavelength. A 2×10 mm2 path length quartz cell was used for
all fluorescence measurements to avoid any blue edge distortion of the spectrum
due to inner filter effect [16].
2.7. Scanning electron microscopy
SEM was done using a Quanta 200 FEG model No. D7722 (XTM @ 2001
FEI Company) scanning electron microscope. Samples were spread on the glass
cover slip and allowed to dry in room temperature before recording. All samples
were recorded at room temperature. We have focused in the region where the
salts of buffer were not deposited and clear images of mitochondria were found.
2.8. Transmission electron microscopy
The Transmission Electron Microscopy (TEM) was performed with a
Hitachi electron microscope model 600 operating at 75 kV with a resolution of
5 Å. The samples were spread over copper grids coated with carbon. 2% PTA
was used as the negative stain for DMPC vesicles.
2.9. UV-Visible absorption spectroscopy
All the absorption spectrum given in different figures were recorded with
Thermo Spectronic spectrophotometer model UNICAM UV500. Baseline
correction was done with corresponding buffer before recording each set of data.
Samples were deoxygenated by passing argon gas for about 20 min before
scanning to avoid photochemical changes due to presence of oxygen.
2.10. Circular dichroism
CD spectra were recorded with a Jasco J-720 spectropolarimeter using
cylindrical quartz cuvette of path length 2 mm. Each spectrum represents the
average of five successive scans performed at a scan speed 20 nm/min.
Appropriate baseline subtraction and noise reduction analysis using identical
window were performed in each case. All spectra were recorded at 298 K.
3. Results
3.1. Effect of piroxicam on mitochondrial membrane and
membrane mimetic systems
In order to study the interaction of piroxicam with
mitochondria, experiments were done on mitochondria isolated
from cell line V79, Chinese Hamster lung fibroblast, according
to the procedure described in Experimental procedures,
suspended in PBS buffer (pH 7.4) containing 0.2% (v/v)
DMSO. No Ca2+ or oxidative substrates were added. Mito
Tracker Green FM is a dye used for staining mitochondria. In
aqueous buffer, this dye is almost non-fluorescent. On
incorporation into mitochondria, it gives a strong fluorescence
at an emission maximum of 516 nm [17]. Fig. 1(A) shows the
fluorescence spectrum of Mito Tracker Green FM (20 nM) in
aqueous buffer and in presence of mitochondria under
conditions as mentioned above. To study whether piroxicam
is capable of permeabilizing mitochondrial membrane in
isolated mitochondria, they were first treated with piroxicam
(20 μM) and the fluorescence peak intensity at 516 nm was
monitored with time at 37 °C. A decrease in fluorescence
intensity would result if the dye were released in aqueous bufferon mitochondrial membrane permeabilization. Fig. 1(B) shows
the time dependent decrease in the intensity of the dye for
mitochondria treated with piroxicam and that of the untreated
ones. The data presented are the average of three separate
experiments. The decrease in the intensity of the dye for
piroxicam treated mitochondria is consistently more than that of
the control. The difference is around 9% at the end of 7 h. This
indicates that the presence of piroxicam results in additional
permeabilization with the subsequent release of the dye into the
aqueous buffer. In order to see whether this additional decrease
in fluorescence intensity of the dye, in presence of piroxicam, is
not due to direct quenching of the dye by piroxicam, the
interaction of piroxicam with the dye in absence of isolated
mitochondrion was followed for the same time period. The
experimental conditions and concentrations of the dye and
Fig. 2. SEM photograph of (A) isolated mitochondria in PBS buffer at pH 7.4 without adding piroxicam (B) after 5 h incubation with 20 μM piroxicam, (C) enlarged
image of a fused mitochondria, (D) enlarged image of a typical ruptured mitochondria.
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isolated mitochondria. It is evident from Fig. 1(B) that no
interaction between piroxicam and MitoTracker Green FM
occurs within the time frame studied, resulting in no significant
change in the fluorescence intensity of the dye. This clearly
shows that the decrease in the fluorescence intensity of the dye
in presence of the drug is due to release of the dye from the
mitochondria into the aqueous buffer. The 9% additional
decrease in the intensity for piroxicam treated mitochondria
compared to that of the control is small but significant.
Scanning electron microscope was used to image directly the
effect of piroxicam on isolated mitochondria,. Fig. 2(A–D)
show SEM photographs of isolated mitochondria for both
untreated and treated with piroxicam. Fig. 2(A) is that of the
isolated mitochondria in absence of piroxicam, whereas Fig. 2
(B) shows the SEM photograph of the same mitochondria as
Fig. 2(A) but treated with 20 μM piroxicam for 5 h. Fig. 2(B)
clearly shows the presence of fused mitochondria indicated by
white arrows. This is not seen in Fig. 2(A). A fused
mitochondria is enlarged in Fig. 2(C). The typical dumbbell
shape characterized by the presence of a ‘stalk’ between two
fused mitochondria is similar to that proposed/ observed in Case
of fusion of other membrane mimetic systems [18,19]. Fig. 2(D)is the enlarged SEM photograph of a ruptured mitochondria. It
should be mentioned, that for untreated mitochondria as shown
in Fig. 2(A), there exist no fused bodies or ruptured
mitochondria. However due to the stringent condition imposed
on the system to record the SEM photographs (mentioned in
Experimental procedures), there has been significant swelling in
the volume of mitochondria. This is obvious in the hetero-
geneity of the sizes as seen in Fig. 2(A). In order to demonstrate
that the change brought about in the morphology of
mitochondrial membrane is a general property of piroxicam,
studies were carried out on membrane mimetic systems, viz.,
mixed micelles and liposomes. Fig. 3(a) shows the transmission
electron micrograph of mixed micelles formed from 0.1 mM
CTAB and 15 mM SDS, in absence [Fig. 3a(i)] and in presence
of 30 μM piroxicam [Fig. 3a(ii)], incubated for 2 h. The TEM
photograph of mixed micelles in absence of piroxicam is clearly
a poly disperse solution without any fusion bodies. When the
same mixed micellar system was treated with 30 μM piroxicam,
several fusion bodies appeared. The typical ‘ball and stalk’
figure characteristics of hemi-fusion is seen indicating that the
drug can induce fusion in mixed micellar system. Similar
observation was made in case of DMPC liposomes. Fig. 3b(i)
shows the TEM photograph of untreated DMPC liposomes. No
Fig. 3. TEM photograph of [a(i)] mixed micelles of 0.1 mM CTAB and 15 mM SDS at pH 7.4, [a(ii)] mixed micelles of same composition incubated with 30 μM
piroxicam for 2 h, [b(i)] DMPC vesicles in MOPS buffer at pH 7.4 [b(ii)] DMPC vesicles incubated for 2 h with 30 μM piroxicam at pH 7.4.
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the DMPC liposomes with 30 μM piroxicam as is evident in
Fig. 3b(ii). Figs. 2 and 3 indicate that induction of membrane
fusion is a general property of piroxicam. It is this fusogenic
property that allows the drug to change the mitochondrial
membrane morphology leading to fusion and subsequent
rupture.
3.2. Piroxicam induced cytochrome c release and Caspase-3
activation in V79 Chinese hamster lung fibroblast cell
The results presented above lead to the question whether
modulation of mitochondrial membrane by piroxicam can have
any consequence at the cellular level. Studies were carried out
on V79 Chinese Hamster Lung Fibroblast cell line, the same
cell line used to isolate mitochondria for the experiments
mentioned in the previous section. Cells were incubated in
absence and in presence of piroxicam at increasing doses of20, 40 and 100 μM for a period of 8 h. A positive control for
cytochrome c release is included using 1 μM staurosporine
treated cells under identical condition. The treated and
untreated cells were ruptured and immunoblot analysis for
the detection of cytochrome c was performed on the cytosolic
fraction. It is clear that in piroxicam treated cells, cytochrome
c is released in the cytosol in a dose dependent manner (Fig.
4A). Fig. 4C shows the band intensity of the released cyto-
chrome c. Cytochrome c release from mitochondria is known
to activate caspases that orchestrate the downstream events
associated with apoptosis. Fig. 4(D) shows the corresponding
increase in caspase-3 activity of V79 cells treated with
increasing concentration of piroxicam. The increase in
caspase-3 activity also occurred in a dose dependent manner.
Release of cytochrome c in the cytosol by piroxicam can occur
by different pathways, but our results indicate that direct
modulation of mitochondrial morphology by the drug could also
be one of the possibilities.
Fig. 4. Cytochrome c release and caspase-3 activation by piroxicam in V79
fibroblasts. (A) Untreated (control) and treated with 20, 40 and 100 μM
piroxicam or 1 μM staurosporine probed with anti-cytochrome c. The
experiments were repeated three times. (B) An immunoblot of cytosolic
fractions isolated form V79 fibroblasts either untreated (control) or treated with
20, 40 and 100 μM piroxicam or 1 μM staurosporine probed with anti-β-actin
antibodies. (C) Band density of cytochrome c either untreated (control) or
treated with 20, 40 and 100 μMpiroxicam or 1 μM staurosporine, (D) Caspase-3
activity in V79 fibroblasts either untreated (control) or treated with 20, 40 and
100 μM piroxicam. Caspase-3 activity is given number of folds increase in
caspase-3 activity over control. Data are presented as the mean for three different
experiments.
Fig. 5. (A) Absorption spectra of a mixture of 50 μM piroxicam and 5 μM
cytochrome c in MOPS buffer (pH 7.4) just after the mixing (……… ..) and after
6 h of mixing (——–), (b Inset) Plot of absorbance at 356 nm vs. time, a
representative decay profile when concentration of piroxicam was 50 μM and
cytochrome c was 5 μM and (B) Plot of Kobs vs. concentration of cytochrome c
at pH 7.4 and 37 °C (correlation coefficient=0.99). Data are presented as the
mean±S.D. for three different experiments.
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After demonstrating the effect of piroxicam on the morpho-
logy of mitochondrial membrane and membrane mimetic
systems as well as its effect on intact cells, we extend our
work to see if the drug can interact with cytochrome c. In the
previous section we have shown that piroxicam is capable of
releasing cytochrome c from the mitochondria. One of the
mechanisms as proposed by us is the direct modulation of the
mitochondrial membrane leading to permeabilization. In this
section we show that piroxicam can directly interact with
cytochrome c leading to the reduction of its heme group. The
kinetics and the mechanism of this interaction are also presented
in this section.
Fig. 5(A) shows the absorption spectrum in the region
500 nm to 600 nm of the mixture of cytochrome c (5 μM) and
piroxicam (50 μM), recorded immediately after mixing andafter a time period of 6 h. The concentration of 50 μM is within
the dose range in which piroxicam can affect the mitochondria
in intact cells as shown in Fig. 4. It should be mentioned that the
same effect of piroxicam on cytochrome c was seen at lower
concentration of 20 μM. Data are presented for the higher dose
of 50 μM which has a better signal to noise ratio. For all
experiments the pH of the solution is maintained at 7.4. Two
peaks at 520 nm and 550 nm replace the broad band between
500–600 nm in the spectrum recorded after 6 h. These two
peaks are characteristics of reduced heme group [Fe(II)] of
cytochrome c [20], which indicates that piroxicam is capable of
slowly reducing cytochrome c. The absorption maximum of the
anionic form (predominant form of piroxicam at pH 7.4) of
piroxicam is at 356 nm. This peak is strongly reduced in the
spectrum recorded after 6 h (data not shown). It should be
mentioned that the disappearance of the 356 nm band and the
appearance of 520 nm and 550 nm doublet do not occur
Fig. 6. (A) Plot of 1/v vs. 1/[Px] for [Px]>>[Cytc] (correlation coeffi-
cient=0.99) and (B) Plot of v vs. [Px] for [Px]<<[Cytc] (correlation
coefficient=0.97), velocity of the reaction (v) was measured at 550 nm,
which is the characteristic absorption maximum of reduced cytochrome c.
Data are presented as the mean±S.D. for triplicate experiments.
1144 H. Chakraborty et al. / Biochimica et Biophysica Acta 1768 (2007) 1138–1146simultaneously. Decrease in the absorbance at 356 nm was
therefore monitored to study the reaction kinetics of the first
phase of the above reaction. Fig. 5(B) inset shows a plot of
absorbance at 356 nm vs. time. It is evident that the decay
profile follows first order reaction kinetics and hence the rate
constant of the reaction (Kobs) can be calculated from the fitting
of the absorbance at 356 nm vs. time (min.) plot to the following
equation
O:Dt ¼ A0 þ A1  expðKobs  tÞ;
where ‘O.Dt’ is the absorbance at 356 nm at time t, A0 and A1
are constants, Kobs is the rate constant of the reaction and t is the
time in min. The Kobs was followed with increasing concentra-
tion of cytochrome c, keeping the concentration of piroxicam at
least 10-fold more. The linear dependence of Kobs on the
concentration of cytochrome c, as shown in Fig. 5(B), has a
non-zero intercept. This indicates that the reaction between
piroxicam and cytochrome c is reversible. As has been
mentioned before, the disappearance of the peak at 356 nm
for anionic piroxicam is not followed by concomitant increase
of the peak at 550 nm belonging to that of reduced cytochrome
c. This is suggestive of the fact that the reaction between
piroxicam and cytochrome c proceeds through the formation of
an intermediate. Since no new band of the intermediate
develops at any point of time it is obvious that the absorption
of the intermediate overlaps with the reactants and / or products.
Hence it was not possible to directly follow the formation as
well as the disappearance of the intermediate spectrophotome-
trically. The late onset of the 550 nm band of reduced
cytochrome c shows that the disappearance of the intermediate
might be the slowest step and hence the rate determining step of
the whole reaction. The rate of reduction of cytochrome c was
measured by monitoring the increase of absorbance at 550 nm.
Keeping in mind the results of Fig. 5(B) inset and Fig. 5(B) and
the above facts, we propose the following scheme of reaction.
ðCytCÞox þ PxYp
k1
k1
½ðCytCÞox  PxYk2 Productþ ðCytCÞred
The above scheme is aMichaelis–Menten like reaction.Under
the condition of [Px]>>[Cytc] (at least 10-fold) the rate of
formation of reduced cytochrome c is dependent on the
concentration of piroxicam at a particular concentration of
cytochrome c.The rate (v) can then be expressed by the following
reaction,
1
v
¼ 1
Vmax
þ KM
Vmax½Px ð1Þ
where v is the rate of the reaction, Vmax is the maximum
velocity for the steady state conversion of the substrate into
product and KM is the Michaelis constant for the substrate. So
the plot of 1/v vs. 1/[Px] will give a straight line, which allows
us to determine the values of KM and Vmax.
Fig. 6(A) shows the plot of 1/v vs. 1/[Px]. v was measured at
550 nm, which is the characteristic absorption maximum of
reduced cytochrome c. For each point, data were recorded thriceand the error bar gives the standard deviation. The value of KM
and Vmax were calculated from Fig. 6(A) and were found to be
121.6 μM and 4.21×10−4 μM min−1 respectively. The KM
value is of intermediate range, which indicates that the
dissociation of the intermediate (Px–CytC complex) is thermo-
dynamically favorable but the low value of Vmax indicates slow
rate of dissociation.
As a double check we have also followed the kinetics under
the condition [Px]<<[CytC] (10-fold). The rate of formation of
reduced cytochrome c is then dependent on the concentration of
piroxicam at a particular concentration of cytochrome c in the
following manner,
v ¼ k2½CytC½Px
KM
ð2Þ
Fig. 6(B) shows the plot of v vs. [Px], which is linear as
expected from the above equation and the rate of the reaction is
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and 6(B) show that our assumption of a reaction scheme, which
is Michaelis–Menten like, is the true representation of the
reaction mechanism between piroxicam and cytochrome c.
There exists a controversy as to whether the structure of
cytochrome c is also altered when the heme group is reduced
[21,22]. Several studies have been devoted to this. In order to
see whether reaction with piroxicam can alter the structure of
cytochrome c along with the reduction of heme group, CD
spectrum of piroxicam and cytochrome c mixture was recorded
immediately after mixing, after 3 h of mixing and after 6 h.
Reduction of 222 nm and 208 nm peak characteristic of α-helix
shows that the reaction with piroxicam results in small but
significant changes in the protein conformation along with the
reduction of Fe(III) (Fig. 7).
4. Discussion
Our results demonstrate the effect of piroxicam on mitochon-
drial membrane morphology, on membrane mimetic systems, on
intact cells and on cytochrome c, a mitochondrial protein.
Piroxicam is a long acting NSAID taking about 6 h to achieve
peak plasma concentration and 40–50 h for complete metabo-
lism [23]. The normal plasma level of piroxicam is 8 μg/ml,
which is 24 μM. The effects exhibited by the drug as described in
results occur at physiologically relevant concentration and time
frame.
The results on isolated mitochondria indicate that mito-
chondria can be permeabilized by piroxicam. The SEM images
show that piroxicam can directly affect mitochondrial
membrane leading to fusion and rupture. Studies on membrane
mimetic systems like DMPC liposomes and mixed micelles
show that, causing membrane fusion is a general property of
piroxicam. Several models have been proposed to explainFig. 7. Circular Dichroism spectra of piroxicam (50 μM)-cytochrome c (5 μM)
mixture just after mixing (——–), after 3 h of incubation (… ... .) and after of 6 h
of incubation (- - - - - - - ).membrane fusion and fusion of membrane mimetic systems by
different fusogenic agents like PEG [24], viral fusion peptide
[25], SNARE proteins [26], etc. Membrane perturbation by
fusogenic agent is a pre-requisite for membrane fusion. The
extent of perturbation directly correlates with the fusogenic
ability of the inducing agent [27–29]. A membrane fusion is a
three-step process: aggregation, followed by disrupted packing
in the contacting bilayer to form the ‘stalk’ and finally mixing
of vesicles contents. It is interesting to speculate on the
mechanism by which piroxicam can induce fusion in
membrane mimetic systems and mitochondrial membranes. It
is reported that piroxicam can decrease the transition
temperature of DPPC bilayers [30]. A decrease in transition
temperature of phospholipid reflects a disordering effect of the
drug on the lipid bilayer [30]. This disordering could lead to
decrease in rigidity of the drug populated vesicles such that it
is highly plausible that random collisions of two such vesicles
becomes less elastic, thereby increasing the propensity for
aggregation followed by fusion. Membrane fusion property of
a NSAID has not been demonstrated before and to our
knowledge, this is the first report on the fusogenic property of
a NSAID.
Modulation of mitochondrial membrane morphology by
piroxicam leading to permeabilization seems to have conse-
quences at the cellular level as seen from our studies on V79
Chinese Hamster fibroblasts. It is clearly seen that piroxicam
can permeabilize mitochondrial membrane and release cyto-
chrome c in a dose dependent manner. Release of cytochrome c
in the cytosol is known to activate caspases that orchestrates the
downstream events that lead to apoptosis. Here we show the
increase in caspase-3 activity by piroxicam, which indicates the
initiation of pro-apoptotic downstream events. Mitochondrial
membrane permeabilization leading to cytochrome c release
has been proposed to occur by different pathways viz., (a) by
swelling of the outer membrane [31–33]; (b) mitochondrial
transition pore (PTP) opening along with the association of pro-
apoptotic protein like Bax [34,35]; (c) alteration of mitochon-
drial membrane morphology. It should be mentioned that
cytochrome c release frommitochondria, achieved by secondary
effectors like proapoptotic Bax protein has not been probed in
this work. We only point out that modulation of mitochondrial
morphology could be one of the many different ways that
piroxicam can permeabilize mitochondria in intact cells.
Interaction of piroxicam with cytochrome c indicates that the
drug can slowly reduce the heme group [Fe(III) to Fe(II)] within
a time frame relevant to its lifetime in blood plasma. This is not
surprising considering that piroxicam can act as an effective
antioxidant agent [36,37], which reflects its capacity as a
reducing agent. We have proposed a scheme of reaction
mechanism, which involves an intermediate that could not be
spectroscopically determined. Despite that, our results on the
kinetics validate the existence of such intermediate. The
Michaelis–Menten like reaction scheme as proposed here
adequately fits to our kinetics data. It should be pointed out
that small structural changes as followed by CD-measurements
is seen in the cytochrome c with the alteration of its redox state
by piroxicam. This is consistent with the recently reported study
1146 H. Chakraborty et al. / Biochimica et Biophysica Acta 1768 (2007) 1138–1146by Sagle et al. [38] which shows that parts of cytochrome c exist
in dynamic equilibrium with locally unfolded state, which in
turn is dependent on the protein's oxidation state.
Finally, we have been able to demonstrate that membrane
fusogenic property of piroxicam leads to permeabilization of
mitochondrial membrane. We propose that one of the possible
pathways by which piroxicam permeabilizes mitochondria leading
to release of cytochrome c and subsequent caspase-3 activation is
by modulation of mitochondrial membrane morphology. We also
demonstrate that piroxicam can reduce cytochrome c by a slow
kinetics, which follows a Michaelis–Menten like reaction scheme
leading to small structural changes to the protein itself.References
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